GW Pharmaceuticals PLC- ADR  

(Public, NASDAQ:GWPH)   Watch this stock  
Find more results for GWPH
-1.67 (-1.27%)
Real-time:   2:25PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 130.06 - 133.59
52 week 92.65 - 140.52
Open 133.44
Vol / Avg. 305,847.00/421,628.00
Mkt cap 3.32B
P/E     -
Div/yield     -
EPS -7.18
Shares 302.46M
Beta 2.65
Inst. own 7%
Mar 14, 2018
GW Pharmaceuticals PLC Annual Shareholders Meeting (Estimated) - 7:00AM EDT - Add to calendar
Feb 5, 2018
Q1 2018 GW Pharmaceuticals PLC Earnings Release (Estimated) Add to calendar
Dec 4, 2017
Full Year 2017 GW Pharmaceuticals PLC Earnings Call - Webcast
Dec 4, 2017
Full Year 2017 GW Pharmaceuticals PLC Earnings Release
Nov 30, 2017
GW Pharmaceuticals PLC at Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 29, 2017
GW Pharmaceuticals PLC at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin -1930.33% -1598.54%
Operating margin -2265.24% -1860.60%
EBITD margin - -1732.34%
Return on average assets -47.59% -33.50%
Return on average equity -55.86% -38.92%
Employees 496 -
CDP Score - -


Sovereign House, Vision Park
United Kingdom - Map
+44-1223-266800 (Phone)
+44-1223-235667 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Officers and directors

Geoffrey W. Guy Executive Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Justin Gover Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Adam David George Chief Financial Officer, Company Secretary, Director
Age: 44
Bio & Compensation  - Reuters
Christopher John Tovey Chief Operating Officer, Executive Director
Age: 49
Bio & Compensation  - Reuters
Julian S. Gangolli Executive Director
Age: 59
Bio & Compensation  - Reuters
James Julian Noble Non-Executive Deputy Chairman of the Board, Senior Independent Director
Age: 55
Bio & Compensation  - Reuters
Cabot Brown Non-Executive Independent Director
Age: 53
Bio & Compensation  - Reuters
Thomas Gerard Lynch Non-Executive Independent Director
Age: 58
Bio & Compensation  - Reuters
Catherine J. Mackey Ph.D. Non-Executive Independent Director
Age: 61
Bio & Compensation  - Reuters
Alicia Secor Non-Executive Independent Director
Age: 54
Bio & Compensation  - Reuters